Ashish Bansal
12PUBLICATIONS
21CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (12)
Sort by Publication Date:
|Sep 24, 2025
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults.Richard G Langley, Guy Gherardi, Anna Coleman
|Jun 29, 2024
Skin pain and sleep quality numeric rating scales for children aged 6 months to 5 years with atopic dermatitis.A S Paller, E C Siegfried, S E Marron
|May 24, 2024
Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.Shawn G Kwatra, Gil Yosipovitch, Sonja Ständer
|Feb 08, 2024
Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis.S Stander, B S Kim, I Guillemin
|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller
|Aug 24, 2021
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older.Eric L Simpson, Amy S Paller, Elaine C Siegfried
Pageof 2
